首页 | 本学科首页   官方微博 | 高级检索  
     


A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory,advanced, and metastatic biliary tract adenocarcinoma
Authors:Weijing Sun MD  FACP  Anuj Patel MD  Daniel Normolle PhD  Krishna Patel MD  James Ohr DO  James J. Lee MD  PhD  Nathan Bahary MD  Edward Chu MD  Natalie Streeter MSN  Summer Drummond MSN
Affiliation:1. University of Kansas School of Medicine, Westwood, Kansas;2. Division of Hematology-Oncology, Department of Medicine, Harvard University and Dana-Farber Cancer Institute, Boston, Massachusetts;3. Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania;4. Texas Oncology, Round Rock, Texas;5. University of Pittsburgh School of Medicine and Hillman Cancer Center at the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania;6. University of Kansas Cancer Center, Westwood, Kansas;7. National Institute for Occupational Safety and Health (NIOSH) Research Branch, Centers for Disease Control and Prevention, Pittsburgh, Pennsylvania
Abstract:
Keywords:biliary tract cancer (BTC)  chemotherapy refractory  cholangiocarcinoma  gallbladder cancer  regorafenib
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号